Chemical Process Development Working Student

TXG stock climbs as legal win and AI deal shape outlook. JACK KELLOGG - UPDATED SEP. 24, 2026, 12:33 PM ET 10x Genomics Inc. stocks have been trading up by 7.52 percent after upbeat coverage of its advancing single-cell sequencing platform. Key takeaways. * Delaware jury backed three Scale Biosciences single-cell patents, awarding $4.8M in damages against Qiagen's Parse Biosciences and opening the door to enhanced damages and a potential U.S. injunction. * A new partnership with Korea-based Lunit brings AI pathology into TXG's Xenium and Atera spatial platforms, aiming to sharpen oncology biomarker discovery for antibody-drug conjugates and immunotherapy. * Street coverage clusters around $68-$70 price targets, with RBC, UBS, and Deutsche Bank all cautious on slowing single-cell growth even as TXG leads in spatial profiling. * TXG trades with an average Overweight rating and a consensus target in the low-$50s, reflecting long-term optimism but near-term debate over growth durability and valuation. * Recent insider sales by the CFO and a director add a modest overhang, even as both insiders maintain sizable Class A positions. Live Update At 12:32:44 EDT: On Thursday, September 24, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 7.52%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. TXG has been on a strong short-term run. From 2026/08/31 to 2026/09/24, 10x Genomics stock climbed from about $62.45 to $81.28, a move of roughly 30%. That's a serious trend, not just noise. The daily chart shows a steady stair-step higher with brief pullbacks, classic momentum behavior that active traders look for. Intraday on 2026/09/24, TXG opened at $75.50, dipped to $74.60, then pushed to $82.09 before settling just above $81. That shows dip-buying strength and aggressive demand into highs. The 5-minute tape is full of higher lows and controlled pullbacks, not wild reversals. Fundamentally, TXG is still a growth story with red ink. Quarterly revenue sits around $151.0M, with gross margin near 70%, but operating loss was about $22.96M and net loss roughly $17.93M. Key profitability ratios are negative, with return on equity and assets both below zero. Yet 10x Genomics carries over $502.5M in cash, low debt, and a current ratio around 5.7, so liquidity is not the problem. For traders, TXG is a classic high-valuation, high-expectation name: pricey on sales and cash flow, but backed by strong balance sheet and sector growth. Why traders are watching TXG right now. TXG is drawing serious attention because the story mixes hard catalysts with a powerful chart. On the legal front, 10x Genomics just scored a Delaware jury win over Qiagen's Parse Biosciences unit. The jury confirmed three Scale Biosciences single-cell patents as valid and infringed, tied to the Evercode Whole Transcriptome product. Damages came in at about $4.8M, based on a 14% royalty from 2021 to mid-2026, and TXG plans to chase enhanced damages, attorneys' fees, and a possible U.S. injunction. For a company with a multi-$B enterprise value, $4.8M is not the story. The signal is that TXG's intellectual property in single-cell analysis holds up in court. That strengthens 10x Genomics' moat and can pressure a rival's U.S. offerings. Yet, even after this win, TXG stock traded down roughly 5% in a weak healthcare/biotech tape, reminding traders that macro flows still matter. On the innovation side, TXG is partnering with Korea-based Lunit to bolt AI pathology (Lunit SCOPE IO) onto its Xenium and Atera spatial platforms. The combo of H&E image analysis with spatial molecular data aims to sharpen tumor characterization and biomarker discovery, especially for antibody-drug conjugates and immunotherapy response prediction. This is long-tail stuff, but it signals that 10x Genomics is leaning into oncology and spatial biology where it already holds more than 60% share in spatial profiling. Wall Street is noticing. RBC launched coverage on TXG at Sector Perform with a $70 target, highlighting double-digit growth and leadership in spatial profiling but flagging roughly flat single-cell revenue for the next five years. UBS came in Neutral at $68, and Deutsche Bank hiked its target from $40 to $70 while keeping a Hold on TXG. Across the board, TXG still carries an average Overweight rating and a consensus target around $52.13, showing the Street likes the long-term story but is respectful of valuation and segment maturity. Layer on insider activity: CFO Adam Taich sold about 46,388 shares (~$3.0M) and director John R. Stuelpnagel sold 20,000 shares (~$1.24M). Both still hold north of 300,000 Class A shares each, so they remain heavily exposed, but multiple sales naturally make shorter-term traders a bit more cautious at elevated prices. Conclusion. TXG sits at a pivotal spot where price momentum, legal wins, and tech partnerships all collide. The stock has ripped from the low-$60s to above $80 while 10x Genomics is still posting quarterly losses and trading at rich price-to-sales and cash-flow multiples. The Delaware patent verdict reinforces the company's single-cell IP, and the Lunit AI pathology partnership deepens its edge in spatial and oncology workflows. At the same time, the Street is openly questioning how long TXG's core single-cell franchise can grow, even as it cheers the spatial biology runway. For active traders, this is a classic battleground between lofty expectations and real execution. TXG's strong cash position, minimal leverage, and >60% spatial share provide a solid base. But the mixed analyst ratings, cautious outlook on single-cell, and recent insider sales tell you not everyone is chasing at these levels. TXG will likely remain highly reactive to news on Atera adoption, spatial growth, and any next steps in the Parse litigation, especially if an injunction or enhanced damages come through. As Tim Sykes loves to remind traders, "patterns repeat, but they don't always complete." As millionaire penny stock trader and teacher Tim Sykes, says, "Small gains add up over time; focus on building wealth gradually, not chasing jackpots.". TXG's recent breakout fits the momentum pattern, but the only way to manage a name like this is with strict rules. Use the news, respect the trend, and, above all, cut losses fast. This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Its content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to Millionaire Media, LLC. for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize its news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities. Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles: Once you've got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market's twists and turns. Dig into StocksToTrade's watchlists here: Buy this stock for a monster Monday move. Want to start next week off with a big win? Its new algorithm may have just uncovered a new dirt-cheap stock with a great chance of moving +100% or more this Monday. ...One ticker...One trade...One MONSTER move... All you have to do is make this one trade on Monday. While I can't promise future performance, previous picks from this new Monday Algo have racked up gains of +149%, +190%, and +536%... in as little as one day. And Millionaire Media, LLC. think this new pick could be just as big. But if Millionaire Media, LLC. is right, it may move FAST... How much has this post helped you? (0 votes, average: 0 out of 5)

QIAGEN will hold an extraordinary general meeting of shareholders on 6 November 2026 to vote on appointing Jonathan M. Pratt to the managing board. Pratt joined the Netherlands-based molecular diagnostics company as chief executive officer on 1 September 2026. Shareholders will also vote on discharging Thierry Bernard, who stepped down as CEO and managing board member on 1 September. Subject to approval, Pratt would join Roland Sackers, chief financial officer, as the two managing board members. The meeting will take place at 14:00 CET in Venlo, Netherlands. QIAGEN serves over 500,000 customers worldwide in life sciences and molecular diagnostics, employing approximately 5,500 people across more than 35 locations.

GMCA allocates another £163m from Good Growth Fund. 18 September 2026 08:38 Dan Whelan Some £53m of grant funding will go towards transport projects across the city region, with another £25m supporting innovation initiatives and £70m of grants and loans helping to deliver 789 homes in Manchester. The Greater Manchester Combined Authority has earmarked £163m for a range of projects in the latest round of allocations from its £2bn Good Growth Fund. The allocations made this month take the total pledged from the fund beyond £1bn since its launch in November. The fund cobbles together various devolved monies, £500m from the National Wealth Fund, and private investment from the Greater Manchester Pension Fund. It provides a range of products including grants, patient equity, and loans. A total of 52 Good Growth Fund funding submissions seeking approximately £782m were received in the latest call for projects. Below are the successful submissions. Housing allocations. A mixture of grants, loans, and subsidised loans have been awarded in principle to support the creation of almost 800 homes. * A £21.8m loan for Linear Living's 251-flat No1 Lord Street in Cheetham Hill * A £28m grant to plug a viability gap in FEC's Red Bank neighbourhood within the wider Victoria North and deliver 478 homes. The grant is dependent on Victoria North securing government funding as part of the New Towns programme * A £4m grant for 144 affordable homes - including 84 for social rent - in Ordsall to be delivered by Seddon Construction for Salford City Council's RP Derive * A £19m subsidised loan for Urban Splash to deliver the final 60 homes in New Islington. Transport allocations. GMCA has allocated £53m of grant funding towards transport projects in the latest round of allocations. * £24.2m for active travel and public realm improvements around Mill Gate Shopping Centre in Bury to support Bruntwood's redevelopment of the retail centre proposes the creation of 300 homes and 40,000 sq ft of workspace * £2.5m for a CyanLines route linking Manchester city centre with the Etihad stadium and campus * £16.1m for a mobility hub at MIX Manchester next to Manchester Airport * £9.9m for active travel and public realm improvements to support phase one of the Crescent Salford masterplan, being delivered by ECF for the University of Salford Innovation allocations. Around £26m of grants will go towards three innovation initiatives in advanced manufacturing, life sciences, and low carbon tech. * £4.85m for life sciences outfit Qiagen Precision Diagnostics to support the creation of 18,000 sq ft of lab space in Manchester * £16m for FUSE-M to create a 17,000 sq ft facility at Manchester Metropolitan University "bringing together creative and immersive technologies with engineering and manufacturing capabilities" * £4.84m investment into the University of Salford's Energy House to introduce a solar-radiation testing capability. Revised allocations. In earlier allocation rounds, Muse or ECF - which Muse is a part of - was awarded a combined £101m for residential projects in Salford, Stockport, and Oldham for a combined 948 units. Changes in appraisals and delivery approaches have resulted in revisions to the allocations. * An increase of £2m for Stockport 8 * An increase of £16.8m at Adelphi Village in Salford * A decrease of £21.1m in Oldham